PPT-Biomarkers in cardiac diseases

FAINELLI Manon BOGÓ Ákos Szakács Júlia MD Department of Pathophysiology Numbers Cardiovascular diseases The most frequent cause of death 75 millions of death year Important concerns in developed countries. Leslie M Shaw & John Q . Trojanowski. Magdalena Korecka. Michal Figurski. Teresa . Waligorska. Magdalena Brylska. Leona Fields. Nirali. Shah. Biomarker Core Aims for ADNI 3. Continue to collect, store, curate and track all . Laurence WEISS. Predictive biomarkers in HIV infection. Reflect. The extent of immune deficiency. The level of HIV replication and of HIV reservoir. The level of chronic immune activation/inflammation. A Rigorous Discovery-Validation Path Was Taken. 2. Discovery Study. 340 proteins analyzed . (. including KIM-1, urine NGAL, plasma NGAL, . Cystatin. -C, IL-18, pi-GST, and L-FABP). Validation Study. Primary Endpoint: moderate to severe AKI (KDIGO stage 2-3) within 12 hours of . ASCO June 2014. Susan Dent. Medical Oncologist. The Ottawa Hospital Cancer Center. Ottawa, Canada. The problem . Cancer Survivors (Million) 2012 - 2018. Brigham, MGH. MSK. U Penn. Medstar. Washington. Worldwide Trends . 2014. What is a Biomarker?. Worldwide Trends. 2014. What is a Biomarker?. A biological marker, better known as a “biomarker”, is a characteristic . that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic . James L. Cook, DVM, . PhD. Director, Comparative Orthopaedic Lab & . Mizzou. . BioJoint. Center. cookjl@health.missouri.edu. Osteoarthritis (OA): . Everyone’s Problem. Markets. Canine. 78M companion dogs in US (2015 APPA Survey). Schistosoma mansoni. in . Biomphalaria glabrata. Benson Otarigho. 1,3. ,. , . Leandro Xavier Neves. 2. , . Ananda. Lima Sanson. 2. , . Mofolusho. O. Falade. 1. , William Castro-Borges. 2. 1. Cellular Parasitology . V. entricular Remodeling During . E. ntresto Therapy for . H. eart . F. ailure . (PROVE-HF; NCT02887183). James L. Januzzi MD. 1,2. , Margaret F. Prescott PhD. 3. , . Javed. Butler MD MPH MBA. 4. , G. Michael . V. entricular Remodeling During . E. ntresto Therapy for . H. eart . F. ailure . (PROVE-HF; NCT02887183). James L. Januzzi MD. 1,2. , Margaret F. Prescott PhD. 3. , . Javed. Butler MD MPH MBA. 4. , G. Michael . Lec. 3 Part 1. 3. rd. Grade – Fall Semester 2021-2022. . Goran N. Saleh . goran.nori. @tiu.edu.iq. 22/11/2021. BIOMARKER. “A . biomarker . is a substance . used . as. . an . indicator . of . a biologic. a measurable indicator . that . can . tell . us something about a person’s health or disease . state, for example, . disease (pathological) processes in the body, for example, disease stage. , . biological processes in the body (heart rate, blood pressure, temperature), . Authors: . Kieu Vu, John . Arend. , Nichole . Cadez. , Deb Darnell, Valerie . Somma. , . Randi Rycroft, . Loria. Pollack, . Paran. . Pordell. . Women’s Wellness Connection. BCCP (Triple negative breast cancer). . . failure of the heart to pump blood adequately. Cardiac failure is manifested by two ways---. 1) . C.O.. 2) . C.O.. . . . Division of Cardiac Surgery. Department of Cardiac Sciences. King Saud University Medical city. King Saud University, Riyadh.. Objectives of the lecture . Overview of diseases of heart, where surgery can play a role.